Site search
2957 results for '' found
Effect of Coseal at the time of durable left ventricular assist device implantation on orthotopic heart transplantation (ACTRN12625000599471)
Effect of Coseal at the time of durable left ventricular assist device implantation on orthotopic heart transplantation (ACTRN12625000599471)
/
Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with or without heparin (NCT07288489)
Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with or without heparin (NCT07288489)
/
A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 [EMBARQ-CSU LTE] (NCT072
A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 [EMBARQ-CSU LTE] (NCT072
/
Changing Anxiety Response with Emotional Support [CARES] (ACTRN12626000170325 )
Changing Anxiety Response with Emotional Support [CARES] (ACTRN12626000170325 )
/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation [REVEAL-ND NPM
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation [REVEAL-ND NPM
/
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer [CAR NK] Cell Therapy, in Subjects with Immune-Mediated Diseases (NCT06733935)
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer [CAR NK] Cell Therapy, in Subjects with Immune-Mediated Diseases (NCT06733935)
/
Perioperative Medicine Platform Trial (NCT07186634)
Perioperative Medicine Platform Trial (NCT07186634)
/
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders (NCT07104565)
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders (NCT07104565)
/
LOTUS - Low dose combinations to improve stroke outcomes (ACTRN12624001279516)
LOTUS - Low dose combinations to improve stroke outcomes (ACTRN12624001279516)
/
Screening for cardiac amyloidosis in patients with new conduction disease at the Alfred (ACTRN12624000520538)
Screening for cardiac amyloidosis in patients with new conduction disease at the Alfred (ACTRN12624000520538)
/